期刊文献+

贝伐珠单抗联合TPLF方案治疗晚期胃癌临床观察 预览

Clinical Observation on Bevacizumab Combined with TPLF Regimen in the Treatment of Advanced Gastric Cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨贝伐珠单抗联合TPLF方案治疗晚期胃癌的临床疗效及对患者外周血循环肿瘤细胞(CTCs)的影响。方法选取医院2015年6月至2018年6月收治的晚期胃癌患者104例,随机分为观察组和对照组,各52例。两组患者均采用TPLF方案化疗,观察组加用贝伐珠单抗。两组均以21 d为1周期,共治疗3个周期。结果观察组近期有效率为78.85%,明显高于对照组的57.69%(P<0.05);治疗3个周期后,两组患者血清癌胚抗原(CEA)和糖类抗原199(CA199)水平均明显降低,且观察组明显低于对照组(P<0.05);治疗后CTCs阳性率,观察组与治疗前比较无明显差异(P>0.05),对照组与治疗前比较明显升高(P<0.05),且观察组明显低于对照组(P<0.05);治疗期间,两组患者各类、各级不良反应发生率均相当(P>0.05)。结论贝伐珠单抗联合TPLF方案治疗晚期胃癌有一定近期疗效,并可降低CTCs阳性率。 Objective To investigate the clinical efficacy of bevacizumab combined with TPLF regimen in the treatment of advanced gastric cancer and its effect on peripheral blood circulating tumor cells(CTCs).Methods Totally 104 patients with advanced gastric cancer admitted to our hospital from June 2015 to June 2018 were selected and randomly divided into the observation group and the control group,52 cases in each group.The patients in the two groups were treated with TPLF chemotherapy regimen,on this basis,the patients in the observation group were treated with bevacizumab.Both groups were treated for 3 cycles with 21 d as one cycle.Results The short-term effective rate of the observation group was 78.85%,which was significantly higher than 57.69%of the control group(P<0.05).After 3 cycles of treatment,the levels of serum carcinoembryonic antigen(CEA)and glycoantigens 199(CA199)in the two groups were significantly decreased,and those in the observation group were lower than those in the control group(P<0.05).After treatment,the positive rate of CTCs in the observation group was not significantly different from that before treatment(P>0.05),while that in the control group was significantly increased(P<0.05),and that in the observation group was lower than that in the control group(P<0.05).During the treatment,the incidence of all kinds of adverse reactions in the two groups was similar(P>0.05).Conclusion Bevacizumab combined with TPLF regimen has short-term efficacy in the treatment of patients with advanced gastric cancer,which can reduce the positive rate of CTCs.
作者 李向荣 李萍 刘晓丽 LI Xiangrong;LI Ping;LIU Xiaoli(Department of Oncology,Xiaogan Central Hospital,Xiaogan,Hubei,China 432100)
出处 《中国药业》 CAS 2019年第22期38-40,共3页 China Pharmaceuticals
基金 湖北省卫生厅科研项目[WJ2017M239]。
关键词 晚期胃癌 贝伐珠单抗 TPLF化疗方案 外周血循环肿瘤细胞 临床疗效 advanced gastric cancer bevacizumab TPLF chemotherapy regimen peripheral blood circulating tumor cells clinical efficacy
作者简介 第一作者:李向荣,男,硕士研究生,副主任医师,研究方向为肿瘤学,电子信箱:zhao57115397@163.com;通信作者:刘晓丽,女,大学本科,副主任护师,研究方向为肿瘤学,(电话)0712-2833914。
  • 相关文献
投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈